NCT03044223 Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
| NCT ID | NCT03044223 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | Pseudomonas Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2014-08 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2014-08 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and function.
Eligibility Criteria
Inclusion Criteria: * age \> 18 years * critically ill patients with sepsis * microbiologically proven infection with Pseudomonas aeruginosa Exclusion Criteria: * life expectancy \< 24 hours * participation in other studies
Contact & Investigator
Manfred Weiss, MD, MBA
PRINCIPAL INVESTIGATOR
University Ulm, University Hospital Ulm
Frequently Asked Questions
Who can join the NCT03044223 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Pseudomonas Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03044223 currently recruiting?
Yes, NCT03044223 is actively recruiting participants. Contact the research team at manfred.weiss@uniklinik-ulm.de for enrollment information.
Where is the NCT03044223 trial being conducted?
This trial is being conducted at Ulm, Germany.
Who is sponsoring the NCT03044223 clinical trial?
NCT03044223 is sponsored by University of Ulm. The principal investigator is Manfred Weiss, MD, MBA at University Ulm, University Hospital Ulm. The trial plans to enroll 100 participants.